ライフサイエンスコーパス: skin toxicity

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ed with RT (xerostomia, mucositis, and local skin toxicity).

2 ulation in the skin and heart and eliminated skin toxicity.

3 th the observed moist desquamation radiation skin toxicity.

4 mpletion of chemoradiation or on recovery of skin toxicity.

5 mcitabine, including two instances of severe skin toxicity.

6 hough it is efficacious, erlotinib can cause skin toxicity.

7 Common adverse events (all grades) were: skin toxicity (150 mg, 29%; 300 mg, 67%), diarrhea (150

8 atin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infectio

9 f 219 patients vs 39 [18%] of 218 patients), skin toxicity (41 [19%] vs none), lethargy (45 [21]% vs

10 gefitinib vs six [3%] of 225 on placebo) and skin toxicity (46 [21%] vs two [1%]), both mostly grade

11 Skin toxicity and diarrhea were more frequent in the CAP

12 ivery vectors and diagnostic agents, but the skin toxicity and irritation potential of QDs are unknow

13 Skin toxicities are the most common adverse events with

14 29 reported grade 2 toxicities, with grade 2 skin toxicities being the most frequent (16 of 67; 24%).

15 to pre-emptive or reactive treatment (after skin toxicity developed).

16 e potential of Raman spectroscopy to predict skin toxicity due to tyrosine kinase inhibitors treatmen

17 The incidence of specific >or= grade 2 skin toxicities during the 6-week skin treatment period

18 incidence of protocol-specified >or= grade 2 skin toxicities during the 6-week skin treatment period

19 incidence of protocol-specified >or= grade 2 skin toxicities during the 6-week skin treatment period.

20 inhibitors, which are known to induce severe skin toxicity; for this pilot study, three patients were

21 Patient 2 experienced skin toxicity from the conditioning regimen and hyperten

22 sthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients).

23 dverse events of immediate radiotherapy were skin toxicity (grade 1 in 50 [54%] and grade 2 in four [

24 verse events in the treatment group included skin toxicity, impaired activity, damage to surrounding

25 ive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhib

26 The hazard ratio for survival by skin toxicity in cetuximab-treated patients was 0.42 (95

27 Despite reports of skin toxicity in hemochromatosis, little is known about

28 tems could have significant implications for skin toxicity in living subjects.

29 Skin toxicity in patients receiving cetuximab has been a

30 f Raman spectroscopy to detect apparition of skin toxicity in patients treated with tyrosine kinase i

31 Grade 3-4 skin toxicity occurred in 62 (13%) patients given panitu

32 The objective was to characterize the skin toxicity of benznidazole in patients with Chagas di

33 s one [<1%] in the erlotinib group), whereas skin toxicity (one [<1%] vs 22 [16%]) was the most frequ

34 Grade 3/4 skin toxicity or diarrhea was encountered in five and th

35 Skin toxicity outside of the RT field was not strictly d

36 At 17 mg/m(2)/d, skin toxicity required a 2-week treatment break for all

37 d according to the National Cancer Institute skin toxicity scale, offering a basis for describing cut

38 Both findings were independent of skin toxicity that was itself significantly correlated t

39 The incidence of grade 3 skin toxicities was reduced in patients who were treated

40 The observed rate of > or = grade 2 skin toxicity was 0% (0 of 25; one-sided 95% CI, 0% to 1

41 The incidence of skin toxicity was 84% regardless of treatment arm.

42 In contrast to other reports, development of skin toxicity was a statistically significant predictor

43 Skin toxicity was common.

44 Cycle 1 CTCAE skin toxicity was higher in the ULABTKA arm but not sign

45 Skin toxicity was present in 37 patients (62%), and diar

46 Performance status and development of skin toxicity were found to be strong predictors of resp

47 Expected dose-related diarrhea and skin toxicity were observed in gefitinib-treated patient

48 lains the basis underlying sorafenib-induced skin toxicity, with important implications for the thera

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。